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Safety and Risk-Benefit Profile of Microbubble Contrast Agents in Echocardiography
Ultrasound contrast agents capable of transpulmonary passage following intravenous injection have been commercially available since the 1990s. These agents are microbubbles, which are smaller than red blood cells and persist long enough (due to reduced rate of gas diffusion) to reach the left ventricle (LV). [1] [2] [3] Ultrasound contrast agent applications included LV cavity opacification, enhancement of spectral Doppler signals, and evaluation of myocardial perfusion at rest or post-stress. 3 The commercially available second-generation ultrasound agents are approved by the US Food and Drug Administration (FDA) only for the enhancement of LV endocardial delineation in patients with baseline suboptimal examinations. 3 There are currently two commercially available ultrasound contrast agents in the US: Optison™ (perflutren proteintype A microspheres, GE Healthcare, Buckinghamshire, UK) and Definity ® (perflutren lipid microspheres, Lantheus Medical Imaging, North Bellirica).
Efficacy of Ultrasound Contrast Agents
Although tissue harmonic imaging has significantly enhanced the diagnostic quality of baseline transthoracic echocardiography, 4 the increasing prevalence of obesity and lung disease has added an extra layer of challenge;
at least 10-15% of echocardiograms are technically difficult or nondiagnostic despite the use of harmonic imaging. The proportion of nondiagnostic studies is significantly increased during stress echocardiography and in echocardiograms performed in the intensive care unit.
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In non-selected patients, contrast-enhanced echocardiography leads to more accurate assessment of LV volumes and ejection fraction compared with magnetic resonance imaging. 5, 6 Even with the use of harmonic imaging, ultrasound contrast enhances accuracy and reproducibility in calculation of LV systolic function. 6 In selected patients with excellent echocardiographic windows and adequate endocardial visualization of all segments with harmonic imaging, the utilization of contrast echocardiography reduces inter-and intra-reader variability in the assessment of LVEF.
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In patients with abnormal LV systolic function undergoing evaluation for LV remodeling, the use of ultrasound contrast agents reduces reader variability and increases accuracy compared with harmonic imaging with computed tomography as a reference standard. 8 In intensive care patients, the use of ultrasound contrast agents increases the diagnostic yield of both individual myocardial segment evaluation and overall LV function assessment, and should be considered in all patients with non-diagnostic studies. 9 Contrast echocardiography also improves segmental evaluation during dobutamine stress echocardiography 10 and in mechanically ventilated patients, 11 leading to an increased diagnostic yield. Additionally, contrast-enhanced echocardiography reduces the downstream utilization of alternative testing resources, making ultrasound contrast agents cost-effective for rest and stress imaging.
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Adverse Effects and Contraindications Based on
Pre-marketing Studies
In pre-marketing studies, Optison™ was administered to 279 patients. 16 Forty-seven (16.8%) patients reported at least one adverse event. Of these, one event was serious and required treatment with antihistamines for hypersensitivity manifestations of dizziness, nausea, flushing, and temperature elevation. No deaths were reported during the clinical studies.
Headache (5.4%) was the most commonly reported side effect.
One thousand, seven hundred and sixteen patients received Definity in pre-marketing clinical trials. 17 Of these, 144 (8.4%) had at least one treatment-related adverse reaction. There were eight deaths, which were attributed to underlying disorders. There were 11 other serious adverse events, including one hypersensitivity reaction with urticaria and pruritus;
other patients experienced dizziness, chest pain, dyspnea, or back pain.
Headache (2.3%) and back and renal pain (1.2%) were the most common side effects, and resolved spontaneously without treatment.
The use of ultrasound contrast agents is contraindicated in patients with right-to-left, bi-directional, or transient right-to-left cardiac shunts that can allow microspheres to bypass the pulmonary particle-filtering mechanisms and directly enter the arterial circulation, potentially resulting in microvascular occlusion and ischemia. These agents should also not be injected intra-arterially or in patients who have a known hypersensitivity to Taiyeb M Khumri, MD, is a third-year Fellow in General Cardiology at the University of Missouri, Kansas City, of which Saint Luke's Mid-America Heart Institute is an affiliated teaching hospital. He completed one year dedicated to research in the field of echocardiography that focused on the utilization of echo contrast for left ventricular opacification and for myocardial perfusion echocardiography.
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perflutren. The use of Optison is also contraindicated in patients with an allergy to egg (albumin).
US Food and Drug Administration Boxed WarningOctober 2007
In October 2007, the US FDA mandated labeling revisions for both commercially available perflutren-containing ultrasound contrast agents largely based on four reported deaths that were temporally related (but not clearly causally attributable to) ultrasound contrast agent injection. The labeling revisions included a 'Boxed Warning' highlighting the potential for "serious cardiopulmonary reactions," new disease state contraindications including worsening or clinically unstable heart failure, acute myocardial infarction or acute coronary syndrome, serious ventricular arrhythmia or high risk for arrhythmia based on QT interval prolongation, and respiratory failure, severe emphysema, pulmonary emboli, or other conditions that cause pulmonary hypertension. The FDA also mandated a 30-minute monitoring period for all patients following contrast agent injection.
Implications of the US Food and Drug Administration Warning
The FDA warnings and contraindications effectively restricted the use of contrast echocardiography in acutely ill patients; both published data and clinical experience indicated that these were the patients who were most likely to derive diagnostic benefit from the addition of an ultrasound contrast agent.
Immediately following the October 2007 FDA product labeling changes, use of ultrasound contrast agents in the US decreased dramatically, with many medical centers discontinuing contrast echocardiography altogether.
Many echocardiographers were immediately critical of the FDA action, noting that there was no direct evidence for causality in the deaths reported in close temporal association to ultrasound contrast agent injection. Experts also noted the previously documented excellent safety profile of the commercially available agents, the possible confounding effect of 'pseudocomplication' (death or other adverse outcome due to progression of underlying disease and not diagnostic testing or therapeutic intervention), and the known increased risk of other more invasive testing (such as transesophageal echocardiography), which would now be necessary in many patients. 18, 19 Within the past year, several large-scale safety studies have been published that have objectively defined the safety profile of ultrasound contrast agents in nearly 200,000 patients.
Recently Published Safety Data
In a research letter published in the Journal of the American Medical
Association, Herzog reported on 16,025 patients on the Hennepin County Medical Center database who received an ultrasound contrast agent.
Optison was used in 3,051 studies and Definity was used in 12,974 patients. A total of 20 adverse events episodes were recorded, with four serious adverse events (serious adverse event rate 0.03%) and no fatalities.
Many of the adverse events (including the four serious events) were consistent with allergic-type phenomena; in the patients experiencing these events, 65% were women and 65% had a previous history of atopy. 20 Kusnetzky et al. reported a large retrospective analysis of mortality in hospitalized patients undergoing echocardiography with (6,196 patients) and without (12,475 patients) an ultrasound contrast agent at Saint Luke's Hospital System in Kansas City over a three-year period. Twenty-four-hour mortality rates were 0.42% for patients receiving Definity and 0.37% for patients undergoing unenhanced echocardiography (p=not significant). Despite no increased mortality risk in the contrast echocardiography group, these patients exhibited more significant comorbidities and illness severity than those undergoing non-contrast echocardiography. 21 In a large multicenter, retrospective analysis conducted by the American hours compared with a control group who did not receive a contrast agent. 25 Shaikh reported on 5,069 patients who underwent the stress echocardiography procedure; an ultrasound contrast agent was administered to 2,914 of these patients. A higher proportion of both inpatients and patients undergoing dobutamine stress had contrast-enhanced studies. Despite the fact that patients receiving an ultrasound contrast agent tended to be older and were more likely to have reduced LV systolic function, there were no deaths in the group receiving contrast. One uncomplicated acute myocardial infarction and one anaphylactoid reaction occurred in the contrast agent group (p=0.51).
Thus, while ultrasound contrast agents were more likely to be used in older hospitalized patients with depressed LV systolic function, there was no increase in the rates of major adverse events. 
